Genprex Announces Collaboration With Roche Diagnostics For Biomarker Assay Validation Studies
GNPX•Timeline and purpose
The company expects to complete the validation studies by the end of 2026.
Genprex said the collaboration is intended to refine patient identification using the TROP2 biomarker.
Collaboration with Roche Diagnostics
Genprex Inc said it is collaborating with Roche Diagnostics for biomarker assay validation studies.
